Posted by Reuters: Business News on June 7, 2010
NEW YORK/LONDON (Reuters) – Bristol-Myers Squibb Co’s shares rose more than 8 percent on Monday after news over the weekend that its experimental drug ipilimumab extended survival in patients with deadly skin cancer.
Posted by Reuters: Business News on May 17, 2010
TOKYO (Reuters) – Astellas Pharma , Japan’s No.2 drugmaker, agreed to buy U.S. biotech OSI Pharmaceuticals for $4 billion in cash in a sweetened bid that will add OSI’s blockbuster cancer drug Tarceva to its line-up.
Posted by Reuters: Business News on March 29, 2010
LONDON (Reuters) – British cancer specialist Antisoma suffered a body blow on Monday as a lung cancer drug being developed with Novartis failed in a late-stage trial, sending its shares plunging 70 percent.
Posted by Reuters: Business News on March 1, 2010
NEW YORK (Reuters) – Astellas Pharma Inc launched a $3.5 billion hostile bid for OSI Pharmaceuticals to gain access to the blockbuster Tarceva cancer drug, in the latest move by a Japanese drugmaker to make inroads in the United States.
Posted by on December 23, 2009
Abraxis Bioscience, a cancer drug maker listed on the Nasdaq Stock Market, purchased the shell compa…
Source >>>
Posted by on December 22, 2009
Abraxis Bioscience, a cancer drug maker listed on the Nasdaq Stock Market, purchased the shell compa…
Source >>>
Posted by on December 18, 2009
Abraxis Bioscience, a cancer drug maker listed on the Nasdaq Stock Market, purchased the shell compa…
Source >>>
